Teriflunomide

Chemical formula: C₁₂H₉F₃N₂O₂  Molecular mass: 270.207 g/mol  PubChem compound: 54684141

Therapeutic indications

Teriflunomide is indicated for:

Relapsing remitting multiple sclerosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Teriflunomide is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Teriflunomide is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Severe immunodeficiency states

Immunodeficiency

Impaired bone marrow function, significant anaemia, leucopenia, neutropenia, thrombocytopenia

at least one of
Bone marrow disorder
Anemia
Leukopenia
Neutropenic disorder
Thrombocytopenic disorder

Severe active infection

Infectious disease

Renal dialysis

at least one of
Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)
Renal dialysis

Severe hypoproteinaemia

at least one of
Hypoproteinemia
Nephrotic syndrome

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: AUBAGIO Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈